Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy.

Loya J, Zhang C, Cox E, Achrol AS, Kesari S.

CNS Oncol. 2019 Nov 1;8(3):CNS40. doi: 10.2217/cns-2019-0002. Epub 2019 Nov 21.

2.

Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins.

Loya J, Zhang C, Cox E, Achrol AS, Kesari S.

CNS Oncol. 2019 Nov 1;8(3):CNS38. doi: 10.2217/cns-2019-0001. Epub 2019 Nov 21.

3.
4.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
5.

Beyond grade: molecular pathology of malignant gliomas.

Sulman EP, Guerrero M, Aldape K.

Semin Radiat Oncol. 2009 Jul;19(3):142-9. doi: 10.1016/j.semradonc.2009.02.001.

PMID:
19464628
6.

Radioimmunotherapy for high-grade glioma.

De Bonis P, Lofrese G, Anile C, Pompucci A, Vigo V, Mangiola A.

Immunotherapy. 2013 Jun;5(6):647-59. doi: 10.2217/imt.13.43. Review.

PMID:
23725287
7.

Overview on current treatment standards in high-grade gliomas.

Pellerino A, Franchino F, Soffietti R, Rudà R.

Q J Nucl Med Mol Imaging. 2018 Sep;62(3):225-238. doi: 10.23736/S1824-4785.18.03096-0. Epub 2018 Apr 26. Review.

PMID:
29696949
8.

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.

Auffinger B, Ahmed AU, Lesniak MS.

Front Oncol. 2013 Feb 25;3:32. doi: 10.3389/fonc.2013.00032. eCollection 2013.

9.

5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas.

Mahmoudi K, Garvey KL, Bouras A, Cramer G, Stepp H, Jesu Raj JG, Bozec D, Busch TM, Hadjipanayis CG.

J Neurooncol. 2019 Feb;141(3):595-607. doi: 10.1007/s11060-019-03103-4. Epub 2019 Jan 18. Review.

PMID:
30659522
10.

Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.

Wang Y, Jiang T.

Cancer Lett. 2013 May 1;331(2):139-46. doi: 10.1016/j.canlet.2012.12.024. Epub 2013 Jan 20. Review.

PMID:
23340179
11.

Vector therapies for malignant glioma: shifting the clinical paradigm.

Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS.

Expert Opin Drug Deliv. 2008 Apr;5(4):445-58. doi: 10.1517/17425247.5.4.445 . Review.

PMID:
18426385
12.

New therapeutic approaches for malignant glioma: in search of the Rosetta stone.

Auffinger B, Thaci B, Nigam P, Rincon E, Cheng Y, Lesniak MS.

F1000 Med Rep. 2012;4:18. Epub 2012 Sep 5.

13.
14.

Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.

Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, M Nettlebeck D, Han Y, Zhang L, Lesniak MS.

Oncoimmunology. 2015 Apr 2;4(8):e1022302. eCollection 2015 Aug.

15.

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.

Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvão da Silva AP, Lin AH, Valenta DT, Perez OD, Ibañez CE, Chen CI, Pettersson PL, Burnett R, Daublebsky V, Hlavaty J, Gunzburg W, Kasahara N, Gruber HE, Jolly DJ, Robbins JM.

Neuro Oncol. 2012 Feb;14(2):145-59. doi: 10.1093/neuonc/nor199. Epub 2011 Nov 9.

16.

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.

Chen R, Cohen AL, Colman H.

Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0. Review.

PMID:
27334978
17.

Intratumoral Immunotherapy-Update 2019.

Hamid O, Ismail R, Puzanov I.

Oncologist. 2019 Nov 29. pii: theoncologist.2019-0438. doi: 10.1634/theoncologist.2019-0438. [Epub ahead of print] Review.

18.

[Oncolytic potential of recombinant influenza A virus vectors on a model of malignant glioma in vivo].

Shurygina APS, Kartashev AV, Kovanko EG, Kiseleva LN, Pustovalov YI, Slita AK, Zarubaev VV, Belyaevskaya SV, Sirotkin AK, Kiselev OI, Egorov AY.

Vopr Onkol. 2016;62(1):138-45. Russian.

PMID:
30444592
19.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

20.

Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, Tam WWS.

Cochrane Database Syst Rev. 2018 Jan 22;1:CD011551. doi: 10.1002/14651858.CD011551.pub2. Review.

Supplemental Content

Support Center